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Aim: To follow changes (over 2 years) in subgingival bacterial counts of five microbial complexes including
health-related Actinomyces spp. in deeper pockets (]5 mm) after periodontal treatments.
Methods: Eight different treatments were studied: (1) scalingroot planing (SRP); (2) periodontal surgery
(SURG)systemic amoxicillin (AMOX)systemic metronidazole (MET); (3) SURGlocally delivered
tetracycline (TET); (4) SURG; (5) AMOXMETTET; (6) AMOXMET; (7) TET; and (8) SURG
AMOXMETTET. Antibiotics were given immediately following SRP. Subgingival plaque was collected
mesiobuccally from each tooth, except third molars, from 176 subjects, completing the study, at baseline, 3, 6,
12, 18, and 24 months post-treatment and analysed for 40 different bacteria using checkerboard
hybridization. A negative binomial (NB) generalized estimating equation (NB GEE) model was used to
analyze count data and a logistic GEE was used for proportions.
Results: We observed short-term beneficial changes in the composition of the red complex of up to 3 months
by treating subjects with AMOXMETTET. Similar short-term improvements with the same treatment
were observed for Tannerella forsythia and Treponema denticola of the red complex. SURG had also short-
term beneficial effect on Porphyromonas gingivalis. No periodontal treatments applied to severely affected
sites promoted the growth of Actinomyces. Smoking elevated counts of both the red and orange complex
while bleeding on probing (BOP) and gingival redness were also predictors of more red complex counts.
Comparatively similar findings were obtained by analyzing counts and by analyzing proportions.
Conclusions: Although short-term reductions in the counts of the red complex were observed in sites that were
treated with AMOXMETTET, long-term significant effects were not observed with any of the eight
treatments. Poor oral hygiene in patients with severe chronic periodontitis diminished the beneficial effects
of treatment.
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n a previous 2-year study on the clinical effects of
periodontal treatments (1), we found that combining
periodontal surgery (SURG) with systemic amoxicil-
lin (AMOX) and systemic metronidazole (MET), and
locally delivered tetracycline (TET) produced significant
clinical improvement of chronic periodontitis. It was
concluded that both surgical and non-surgical therapies
can be used to arrest chronic periodontitis. SURG
AMOXMETTET gave the best maintenance of
clinical results over a 2-year period. Site-level effects
such as bleeding on probing (BOP), accumulation of
plaque, gingival redness, and suppuration were significant
predictors of further loss of clinical attachment level
(CAL) and increased pocket depth (PD). In this study,
we report the effects of these treatments on subgingival
bacteria.
Studies have demonstrated that five different clusters
or communities of bacteria may be found in subgingival
plaque of subjects with chronic periodontitis. The red
complex consisting of Tannerella forsythia, Porphyromo-
nas gingivalis, and Treponema denticola is frequently
found in deeper periodontal pockets and its presence is
usually preceded by species of the more diverse orange
complex. The red complex is the one most related to
periodontitis clinically. In contrast, species of the yellow,
green, and purple complexes are considered to be host
compatible and are generally associated with healthy
sites. Thus, chronic periodontitis has a polymicrobial
etiology (2).
Systemic or locally applied antibiotics have been used
for years in the treatment of periodontitis. The idea of
using antibiotics in the treatment is that they should lead
to beneficial changes in the composition of the subgingi-
val microbiota by reducing pathogens and allowing the
growth of host-compatible species (3). Previous studies
have shown that systemic treatment with MET, which act
against anaerobic bacteria, has beneficial effects on the
subgingival microbiota of periodontal diseases (4). Fluc-
tuation or at least quantitative changes in the incidence
of potential periodontal pathogens were reported after
administration of MET (5). MET has also been com-
pared directly to other antibacterial substances in the
treatment of periodontitis. All such treatments, including
MET, azithromycin, sub-antimicrobial doses of doxycy-
cline, and scaling and root planing (SRP), reduced counts
of red complex species at 12 months but no significant
differences were detected among treatment groups for
most species (6). The greatest benefits in clinical and
microbiological parameters in smokers with chronic peri-
odontitis were achieved with the use of SRPMET
AMOX (7) and systemic administration of AMOX
MET or MET had a significant effect on the levels of
important periodontal pathogens for 6 months post-
therapy (8). Systemic use of doxycycline or MET
AMOX led to levels of Aggregatibacter actinomycetem-
comitans below detection limits in localized juvenile
periodontitis at 10, 30, and 90 days post-treatment (9).
In smokers, adjunctive local doxycycline caused greater
reduction in the frequency of P. gingivalis after initial and
supportive therapy compared to conventional treatment
(10). Two local drug delivery systems, one containing
MET, the other TET hydrochloride, gave both improve-
ments in microbiological parameters of chronic period-
ontitis (11). The improvement was greater when the local
antibiotic therapies were used as an adjunct to mechan-
otherapy and the results were sustained 90 days follow-
ing therapy. Both AMOX and MET gave significant
decreases in counts of many of the bacterial species
associated with periodontitis, particularly in the red and
orange complexes (12). Reduced red complex species were
maintained up to 12 months, especially in patients treated
with MET. Mestrik et al. (13) found that the AMOX
MET group had the lowest proportions of the red
complex as well as a significant decrease in the propor-
tions of the orange complex bacteria after treatment.
Other authors have reported that the combination of
METAMOX is effective in combating A. actinomyce-
temcomitans- and P. gingivalis-associated periodontal
infections (1416). Cionca et al. (17) reported excellent
clinical results in the antibiotic group (AMOXMET)
regardless of the presence or absence of six classic
periodontal pathogens prior to treatment. Also in a
short-term study, Buchmann et al. (18) found that
AMOXMET accelerated the suppression of the period-
ontal microbiota compared to non-surgical therapy
(SRP), but had limited effect on the elimination of target
isolates during healing. Valenza et al. (19) reported a
favorable outcome after mechanical plaque removal and
systemic AMOXMET, but only a transient effect on
P. gingivalis and T. denticola phylotypes. T. socranskii-like
phylotypes were not affected. Furthermore, Ribeiro et al.
(20) found no improvement in the microbiologic and
immunologic outcome after full-mouth debridement
associated with AMOXMET in the treatment of severe
chronic periodontitis.
Control of periodontal disease may best be obtained
by eliminating or suppressing the causative organisms
and by establishing a host-compatible microbiota. Most
studies have been too short to demonstrate this and
beneficial species have rarely been examined. The number
of species studied has also tended to be too limited to
monitor the effect of treatment on both putative period-
ontal pathogens and host-compatible species. Rather
than concentrating on specific organisms, recent research
has indicated that examination of bacterial complexes
may be more useful for addressing the question of
periodontal pathogenesis and the effects of therapy. By
using checkerboard DNADNA hybridization (21), the
presence and levels of 40 cultivable periodontal species
with a putative pathogenic or a host-compatible role were
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followed for 2 years in this study. Species defined under
each of the five bacterial complexes in subgingival plaque
(2) were assessed before and after different treatments.
In addition, selected Actinomyces species, thought to be
associated with periodontal health were monitored.
Materials and methods
The microbiological data were collected from 217 subjects
with chronic periodontitis at two different periodontal
centres in Boston, USA and Go¨teborg, Sweden (22).
Subgingival plaque was collected mesiobuccally from
each tooth, except third molars. We considered data
from 1,463 teeth with an initial PD of at least 5 mm from
176 subjects who completed the study, giving an average
of 8.3 teeth per subject. The patients were monitored at
baseline and at 3, 6, 12, 18, and 24 months.
The subgingival plaque was sampled separately, after
first removing supragingival plaque, from each site with
individual sterile Gracey curettes and assessed for the
contents of 40 subgingival bacterial species using checker-
board DNADNA hybridizations (21). Each sample was
transferred to a tube containing 0.15 ml TE (10 mM Tris-
HCl, 0.1 mM EDTA, pH 7.6), with 0.15 ml freshly
prepared 0.5 M NaOH added. The samples were boiled
for 5 min and neutralized with 0.8 ml 5 M ammonium
acetate and placed in the extended slot of a Minislot
(Immunogenetics, Cambridge, MA, USA) and concen-
trated on a positively charged nylon membrane (Roche,
Indianapolis, IN, USA) by vacuum and fixed to the
membrane by exposure to ultraviolet light, succeeded by
baking at 1208C for 20 min. The chemiluminescence
signals from each membrane were read using a Lumi-
lmager Workstation (Boehringer-Mannheim, Mannheim,
Germany) and evaluated by comparing the signals
obtained with those of pooled standard samples contain-
ing 106 and 105 bacteria of each of the 40 bacterial
species. The probes used had been tested for specificity
and cross-hybridization, as described previously (21).
The response variables were counts of Actinomyces and
counts of the red, orange, yellow, green, and purple
complexes (2). The treatment effects on individual species
of the red complex were also studied. We evaluated the
long-term benefits of the therapies either individually or
as combinations.
The treatments evaluated were: (1) SRP alone; (2)
SRPSURGAMOXMET; (3) SRPSURGTET;
(4) SRPSURG; (5) SRPAMOXMETTET; (6)
SRPAMOXMET; (7) SRPTET; and (8) SRP
SURGAMOXMETTET. For details concerning
patients, inclusion and exclusion criteria, periodontal
treatments and clinical monitoring Goodson et al. (22)
and Mdala et al. (1) should be consulted. In brief,
exclusion criteria were known allergies to the antibiotics
being used, antibiotic or periodontal treatment within the
last 3 months, pregnancy, nursing, or systemic conditions
that would influence the course of periodontal treatment,
or allergy to AMOX, MET, TET, lidocaine, or chlorhex-
idine. Both males and females of all races who were at
least 20 years of age, had at least 15 natural teeth, and
were in good general health were included in the study.
These patients had at least four teeth with pockets5
mm and at least eight teeth with CAL3 mm. At
baseline, all subjects received SRP performed under local
anaesthesia and usually finished in four weekly visits.
SRP was performed by treating a quadrant at a time
under local anaesthesia at approximately weekly inter-
vals. During SRP treatment, subjects rinsed twice daily
with 0.1% chlorhexidine. Systemic antibiotics were given
as 14 days of medication (MET 250 mg3 and AMOX
500 mg2). This therapy was started immediately after
the first session of SRP and was administered in parallel
to local TET fibre application. Compliance was reported
by the patients. Local antibiotics were given as TET fibres
(Actisite†, Procter & Gamble, Cincinnati, OH, USA) in
pockets ]5 mm immediately after mechanical instru-
mentation at the SRP visits. The fibres were removed
after 7 days, that is, at the next appointment for
quadrant-wise SRP. Surgery was performed at the 3-
month monitoring visit following SRP. Subjects who had
residual PDs ]5 mm and BOP received modified Wid-
man flap surgery at weekly intervals as needed. Chlor-
hexidine, 0.1%, was used as a mouth rinse for 1 min twice
daily during the surgical phase and 2 weeks following the
last surgical session. Each subject was provided with a
powered toothbrush and triclosan-containing toothpaste
and instructed to brush twice daily and to perform daily
interdental cleaning with dental floss, toothpicks, and/or
interdental brushes. At each follow-up visit, the patients’
oral hygiene standard was checked and reinforced when
indicated. Furthermore, at the 12-month recall, all sites
with PD ]5 mm and BOP were subjected to subgingival
mechanical debridement.
Count response models
The Poisson regression model is the basic model for
modelling count data and has a probability distribution
given as
f (y;m)
emi (mi)
yi
yi!
; yi0; 1; 2; :::; ni;m0
where y is the count response random variable and the
parameter m is the mean of the distribution. A unique
feature of this distribution is that its mean is equal to its
variance, a relationship called equidispersion. However,
it is very uncommon to have real data satisfying this
property. In most cases, data are over-dispersed, that is,
the variance is greater in value than the mean. This
distributional assumption may also be violated when
there are excessive zero counts. Yet another assumption
behind the Poisson regression model is the requirement
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that counts are independent of one another. In long-
itudinal studies, data are in the form of panels. Obser-
vations within panels cannot be considered to be
independent but may be highly correlated. In addition,
we had measurements from several teeth per patient,
giving rise to another level of dependence.
The distributional problems discussed above have led
to development of more general count models, which
allow for the modelling of a wide range of count response
situations. The NB model is one of them.
The NB model
The NB model is the traditional model of choice for
modelling over-dispersed Poisson data. It is derived as
a Poissongamma mixture distribution and is basically
an extension of the Poisson model with an additional
ancillary or heterogeneity parameter. Several distinct NB
models have been developed to account for distributional
problems associated with count data (23). A generalized
NB model has a variance function with a characteristic
form of mamp. In the case of the Poisson model, this
heterogeneity parameter is equal to 0 (p0). The
traditional NB regression model (p2) is termed the
NB2 model (24) owing to the quadratic nature of its
variance function mam2. The negative binomial 1 (NB1)
model has a variance function given as mam and is
rightly called a linear parameterization. However, just
like the Poisson model, the NB model may also be over-
dispersed. Both models can be extended and modified to
accommodate any extra correlation in the data that
violate distributional properties of these models.
Violations of distributional properties and
extensions considered
Modelling bacterial count data is often challenging
due to disproportionately high numbers of zeros in the
response variable. In addition to this Poisson violation,
our data were structured in panels, with repeated
observations per tooth and teeth nested within patients.
Zero-inflated count models, which were first introduced
by Lambert (25), have the capacity to handle excessive
zero counts. These models include the zero-inflated
Poisson (ZIP), which is a subset of the zero-inflated
negative binomial (ZINB). The only drawback with these
models is their limited abilities to handle nested or
clustered data from longitudinal studies. This second
problem is addressed by the so-called generalized esti-
mating equations.
Generalized estimating equations
Generalized estimating equations (GEE) (26) is one of
the most widely used statistical methods in the analysis of
longitudinal data (27). It is an extension of the general-
ized linear model (GLM) (28) to account for possible
correlations between the repeated measurements of
an individual over time. GEE, which is a population
averaging panel method, accounts for the correlation
between observations in GLM by introducing a working
correlation matrix and by using robust variance estima-
tors. The method differs from a random effects model,
which is subject-specific, by averaging the model effects
across individuals. The benefit of the GEE approach is
that the correlation matrix can be arbitrarily parameter-
ized. The following correlation structures were considered
for our data; independence, exchangeable, unstructured,
autoregressive, stationary, and non-stationary. The ex-
changeable correlation structure, which had the smallest
quasi-likelihood independence criterion (QIC), was cho-
sen. This structure assumes that the correlations between
all observations within a panel are the same. This implies
that any correlation value within the structure may be
exchanged with any other. However, as stated by Zeger
and Liang (26), the GEE approach is very attractive
because estimates from the GEE method are asymptoti-
cally consistent even if the correlation structure has been
misspecified.
Model description
Let Y(yi2, . . .,yij) be a vector of count response variables
of the bacteria in any of the complexes from i1, . . .,176
subjects with j2, . . .,6 time visits corresponding to 3, 6,
12, 18, and 24 months, respectively. For each yij,
covariates xij are given. We modelled the time course
from visit 2 to visit 6 and made adjustment for baseline
by including the baseline counts as a covariate. As the
GEE is generally restricted to one level of correlation, we
considered teeth as a factor in the model with the form:
log[E(Y jxij)]
b0b1timejb2treatib3ageib4genderi
b5nationlityib6smokingib7plaqueib8BOPi
b9PDib10toothib11ALib12baseline_countsi
b13timejtreati
where E(Y jxij) is the expectation of Y given the co-
variates xij. The parameter estimates b0 through to b13
represent fixed effects associated with the intercept, time
effect, treatment, age, gender, nationality (either Amer-
ican or Swedish), smoking habits, plaque accumulation,
BOP, PD, tooth, CAL, baseline counts, and the interac-
tion of treatment with time. Here, b0 is the intercept,
that is the expected count assuming a model with no
covariates, b1 is a vector of four coefficients representing
the effect of time treated as a factor (relative to visit 2), b2
is a vector of seven coefficients representing the effect of
the seven treatment groups relative to the reference group
SRP and b10 is correspondingly a vector of 28 coefficients
representing tooth effect. Finally, b13 is a vector of 28
coefficients representing the interaction between the
factor time and the factor treatment.
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Correlation structure and model selection
The Akaike information criterion (AIC) (29), which is
normally used for GLM model selection is not applicable
with GEE models. This is because GEE models are not
based on the likelihood function (30). Pan (31) proposed
the quasi-likelihood under the independence model
criterion (QIC) for selecting the best model in GEE
analyses. The QIC value can also be used to select the
best correlation structure. The exchangeable correlation
structure, which had the smallest QIC, was selected.
Then, under the exchangeable correlation structure, the
model with the smallest QIC value among the different
models fitted with this working correlation was consid-
ered to be the best GEE model.
Modelling fractional responses
Fractional response variables are encountered in many
areas of research including biological settings. As data
on proportions are bounded between 0 and 1, the use
of standard linear models becomes less appealing. For
example, assuming that y is a fractional response satisfy-
ing the relation 05y51, then if we implement a standard
linear model, we risk predicting proportions that are
less than 0 or more than 1. This argument also holds for
panel data models. One is faced with the problem of
imposing a positive bound effect on the proportions.
Several approaches of handling data on proportions
have been suggested in the literature. The most commonly
used model is the logistic regression model. We used the
logistic model with GEE to handle the dependence in the
data in the same way as described above for the analysis
of counts. However, it should be noted that the inter-
pretation of the two approaches differs. While the logistic
GEE model looks at the extent to which the treatments
influenced the total composition of the bacteria, the GEE
for counts looked at the extent to which the treatments
influenced the different levels of the bacteria complexes.
Significance level
We performed a rather high number of statistical tests
in this study. To reduce the multiple testing problems,
we used a significance level of 1%, and correspondingly,
we computed 99% confidence intervals in our tables.
However, results that are significant at 5% level are also
indicated, by a single asterisk.
Results
As shown in Table 1, there were no significant baseline
differences between subjects in the control group (SRP)
and those receiving other treatments.
Model interpretation
We present the incidence rate ratios (IRRs) from the NB2
GEE models in Tables 24 and Tables S1S4. The IRR in
part (c) of each table represents the change in counts at a
certain time point for each treatment group relative to the
change in the reference group (SRP). Hence, the IRR
conveys information on relative differences in changes
from 3 months, and not on absolute values. If the IRR
is significantly less than 1, then the treatment group
has experienced a relative decrease of bacterial counts
compared with the development in the reference group,
SRP. Conversely, if the IRR is significantly larger than 1,
then the treatment group has experienced a relative
increase of bacterial counts relative to the development
in the reference group. In the case of the red and orange
complexes, the treatment is considered to be effective
compared with SRP when the IRR is significantly less
than 1. In contrast, higher counts of Actinomyces, which
is associated with periodontal health, are desirable. In this
case, the treatment is considered effective compared with
SRP when the IRR is significantly more than 1. For
example, in Table 2 Actinomyces counts were 1.28 times
higher at 6 months in subjects who were treated with
AMOXMETTET compared to subjects who were
treated with SRP. The other explanatory variables in
Table S4 are interpreted similarly.
To assist in the interpretation of the results, part (a) in
each table reports changes in counts from 3 months for
the reference group (SRP) after adjusting for baseline
counts. For example, in Table 3, counts of the red
complex significantly increased by 77% after 24 months.
Part (b) shows the IRR for changes in counts at 3 months
from baseline compared to the reference group, SRP. For
example, in Table 3 changes from baseline were signifi-
cantly lower by 37% in subjects who were treated with
AMOXMETTET compared to subjects treated with
SRP.
Finally, we tested the joint significance of treatment
and time (and the interaction) to see whether there were
any treatment effects. For the analysis of counts, we
found that the overall tests were significant (pB0.01).
Because of these differences, we shall proceed and report
below the developments in treatment effects that were
observed over time.
Treatment effects over time
From the computed IRR and their confidence intervals
for sites with severe chronic periodontitis in Table 2, we
did not observe significant changes in counts of Actino-
myces. Figure 1 shows the median distribution of
Actinomyces counts in box-plots at baseline. In all
treatment groups, there was very little variation in the
median distribution of Actinomyces counts at baseline.
Figure 2 shows changes in counts of Actinomyces from
baseline for each treatment group. For example, there was
a sharp decrease in Actinomyces counts between baseline
and 3 months in the AMOXMETTET and TET
treatment groups.
Effects of periodontal treatment on bacterial counts
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The median distribution of the red complex counts at
baseline is given in Fig. 3. The IRR for the red complex
counts in sites that had an initial PD of at least 5 mm and
had been treated with AMOXMETTET was 0.63
after 3 months as shown in Table 3 (see also Fig. 4). All
other things being equal and compared to SRP, this
indicates that subjects who were treated with AMOX
METTET had changes in counts of the red complex
significantly reduced from baseline by 37% after 3
months. Significant changes in counts of T. forsythia of
the red complex were also observed at 3 months when
AMOXMETTET and AMOXMET were used
compared to T. forsythia counts in the reference group
SRP at baseline. The two treatments had similar short-
term beneficial changes in the composition of T. denti-
cola, whereas SURG had a short-term effect on P.
gingivalis (not presented).
Figure 5 shows that there were minimal variations in
the median distributions of the orange complex counts at
baseline while Fig. 6 shows that compared to SRP, counts
in the other treatment groups were higher between 12 and
24 months. However, there were no significant beneficial
changes in counts of the orange complex that were
observed over time as shown in Table 4.
In Fig. S1, higher counts of the yellow complex were
observed in the SURG, SURGAMOXMET, and
SURGTET groups compared to the reference, SRP.
However, as shown in Fig. S1A, the three treatment
Table 1. Baseline characteristics of the study subjects
Treatments*
1 2 3 4 5 6 7 8 p
n 26 19 25 22 28 26 25 25 0.44
Age (years) 50912 54912 54911 5499 5397 50910 50910 55912 0.39
Americans (n) 14 8 11 10 15 13 12 12 0.99
Females (n) 13 8 13 9 15 10 15 13 0.78
Smoking status  number (%)
Current smoker 9 (35) 8 (42) 11 (44) 7 (32) 14 (50) 10 (38) 8 (32) 11 (44) 0.91
Mean log counts
Red 13.792.4 13.592.9 13.293.1 13.792.6 13.493.2 13.792.7 13.692.1 13.692.1 0.55
Orange 14.791.7 14.791.8 15.091.5 14.691.9 14.592.0 14.891.9 14.791.9 14.991.5 0.41
Actinomyces 13.292.7 13.891.7 13.492.8 13.492.9 13.592.3 13.392.9 13.592.2 13.692.4 0.43
Yellow 12.292.9 10.993.5 11.593.3 11.693.0 11.893.2 11.893.0 12.392.5 12.092.5 0.52
Purple 12.293.0 12.692.3 12.792.3 12.193.1 12.293.0 11.993.2 12.392.6 12.692.7 0.16
Green 13.492.4 13.991.5 13.492.4 13.492.5 13.392.3 13.392.3 13.591.9 13.592.4 0.31
Percentage of sites with
Plaque 23.6 37.5 26.8 32.4 336.6 27.1 32.8 37.8
Gingival redness 33.5 34.3 33.9 32.6 38.3 33.5 27.8 40.0
Bleeding on probing 50.0 34.9 32.6 41.9 32.3 26.2 44.4 37.2
Mean PD (mm) 6.491.3 6.691.8 6.491.3 6.591.3 6.891.8 6.591.5 6.591.3 6.691.6 0.61
Mean CAL (mm) 6.092.4 5.992.5 6.392.0 6.091.8 6.792.3 6.992.3 6.091.7 6.792.5 0.29
Number of missing teeth 6.695.6 6.895.2 7.394.7 7.894.8 6.695.6 7.395.8 7.994.5 8.295.1 0.82
*The eight treatments were:
1. Scaling and root planing (SRP).
2. SRPsurgery (SURG), systemic amoxicillin (AMOX)metronidazole (MET).
3. SRPSURGlocally delivered tetracycline (TET).
4. SRPSURG.
5. SRPsystemic AMOXMET and local TET.
6. SRPsystemic AMOXMET.
7. SRPlocally delivered TET.
8. SRPSURGAMOXMETlocally delivered TET.
Plus/minus values are mean9standard deviations.
There were no significant baseline differences between patients who were in the control group (SRP) and those receiving other treatments
as evidenced by the large p-values. Box-plots for the mean distribution of the natural log counts of Actinomyces and red, orange, yellow,
purple, and green complexes are given in Figs. 1A, 2A, 3A, S1A, S2A, and S3A, respectively.
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groups had lesser counts of the yellow complex at
baseline. At the 5% significance level, sites that were
treated with SURGAMOXMET had an increase in
counts of the yellow complex of 85% and 70% after 18
and 24 months, respectively, compared to SRP-treated
subjects as shown in Table S1.
Table 2. IRR$ estimates and confidence intervals for Actinomyces counts after adjusting for baseline counts in sites that had an
initial PD]5 mm from the GEE NB model using the exchangeable correlation structure in Stata
Part (c) Comparison made to counts after 3 months
(b) IRR: 3 months 6 months 12 months 18 months 24 months
Treatment effect on Actinomyces counts
Marginal effects
estimate 99% CI
IRR
estimate 99% CI
IRR
estimate 99% CI
IRR
estimate 99% CI
IRR
estimate 99% CI
(a) Reference treatment: SRP 1.48 (0.69, 3.15) 1.43 (0.74, 2.77) 1.42 (0.54, 3.78) 1.06 (0.44, 2.54)
Compared with SRP
SURGAMOXMET 0.83 (0.39, 1.78) 1.03 (0.44, 2.44) 1.44 (0.64, 3.19) 1.26 (0.44, 3.60) 1.69 (0.65, 4.39)
SURGTET 1.09 (0.51, 2.35) 0.95 (0.40, 2.23) 1.19 (0.53, 2.66) 1.07 (0.37, 3.06) 1.45 (0.54, 3.86)
SURG% 0.84 (0.40, 1.77) 1.37 (0.60, 3.12) 1.50 (0.71, 3.20) 1.06 (0.38, 2.95) 1.53 (0.58, 3.99)
AMOXMETTET 0.83 (0.39, 1.77) 1.28 (0.55, 2.95) 1.34 (0.63, 2.86) 1.40 (0.49, 4.03) 0.96 (0.37, 2.46)
AMOXMET 1.15 (0.55, 2.42) 0.90 (0.39, 2.06) 0.90 (0.39, 2.07) 0.91 (0.31, 2.64) 1.09 (0.39, 3.03)
TET 0.94 (0.42, 2.09) 1.05 (0.45, 2.46) 0.91 (0.40, 2.05) 0.86 (0.29, 2.53) 1.31 (0.46, 3.70)
SURGAMOXMETTET 1.35 (0.62, 2.92) 0.93 (0.41, 2.09) 1.00 (0.48, 2.11) 0.86 (0.30, 2.45) 1.18 (0.45, 3.11)
There were no significant changes in counts of Actinomyces that were observed in all treatment groups compared to counts in the
reference group, SRP.
$Incidence rate ratioexp (b).
%SURG was performed 3 months after the baseline visit. Results shown at the 3-month study period were for SRP.
SURGsurgery; AMOXamoxicillin; METmetronidazole; TETtetracycline; IRRincidence rate ratios.
Table 3. IRR$ estimates and confidence intervals for red complex counts after adjusting for baseline counts in sites that had an
initial PD ]5 mm from the GEE NB model using the exchangeable correlation structure in Stata
Part (c) Comparison made to counts after 3 months
(b) IRR: 3 months 6 months 12 months 18 months 24 months
Treatment effect on red complex counts
Marginal effects
estimate 99% CI
IRR
estimate 99% CI
IRR
estimate 99% CI
IRR
estimate 99% CI
IRR
estimate 99% CI
(a) Reference treatment: SRP 1.30 (0.98, 1.71) 1.37 (0.99, 1.90) 1.36 (0.96, 1.93) 1.77 (1.13, 2.78)**
Compared with SRP
SURGAMOXMET 1.05 (0.61, 1.80) 0.96 (0.58, 1.62) 1.08 (0.61, 1.94) 0.81 (0.47, 1.41) 0.52 (0.24, 1.12)
SURGTET 0.95 (0.71, 1.29) 0.92 (0.57, 1.48) 0.87 (0.50, 1.53) 0.96 (0.54, 1.69) 0.72 (0.40, 1.32)
SURG% 1.06 (0.65, 1.70) 1.01 (0.59, 1.73) 0.79 (0.36, 1.75) 0.96 (0.49, 1.90) 0.88 (0.41, 1.90)
AMOXMETTET 0.63 (0.43, 0.92)** 0.97 (0.62, 1,52) 1.43 (0.84, 2.43) 1.81 (1.07, 3.06)** 1.23 (0.58, 2.60)
AMOXMET 0.75 (0.50, 1.14) 0.98 (0.59, 1.64) 1.29 (0.56, 2.95) 1.08 (0.54, 2.15) 1.14 (0.51, 2.52)
TET 0.96 (0.68, 1.35) 0.85 (0.47, 1.53) 1.08 (0.61, 1.91) 1.19 (0.62, 2.30) 1.01 (0.50, 2.04)
SURGAMOXMETTET 0.91 (0.60, 1.39) 0.78 (0.43, 1.40) 0.99 (0.56, 1.78) 0.89 (0.46, 1.75) 0.74 (0.34, 1.63)
We observed a 3-month significant reduction in changes of the red complex counts from baseline of 37% in subjects treated with AMOX
METTET compared to SRP-treated subjects. No other significant reductions of the red complex counts in sites with severe chronic
periodontitis were observed from all study treatments compared to SRP-treated subjects.
$Incidence rate ratioexp (b).
%SURG was performed 3 months after the baseline visit. Results shown at the 3-month study period were for SRP.
**Significant results at a0.01.
SURGsurgery; AMOXamoxicillin; METmetronidazole; TETtetracycline; IRRincidence rate ratios.
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Table 4. IRR$ estimates and confidence intervals for orange complex counts after adjusting for baseline counts in sites that had
an initial PD ]5 mm from the GEE NB model using the exchangeable correlation structure in Stata
Part (c) Comparison made to counts after 3 months
(b) IRR: 3 months 6 months 12 months 18 months 24 months
Treatment effect on orange complex
counts
Marginal effects
estimate 99% CI
IRR
estimate 99% CI
IRR
estimate 99% CI
IRR
estimate 99% CI
IRR
estimate 99% CI
(a) Reference treatment: SRP 0.90 (0.68, 1.18) 0.89 (0.67, 1.19) 0.82 (0.66, 1.02)* 1.02 (0.75, 1.37)
Compared with SRP
SURGAMOXMET 0.90 (0.68, 1.18) 1.04 (0.74, 1.46) 1.09 (0.76, 1.58) 1.39 (1.04, 1.88)** 0.97 (0.68, 1.39)
SURGTET 0.92 (0.70, 1.21) 1.14 (0.77, 1.70) 1.18 (0.82, 1.70) 1.36 (0.97, 1.91)* 1.05 (0.71, 1.56)
SURG% 0.88 (0.62, 1.24) 1.20 (0.76, 1.89) 1.08 (0.71, 1.64) 1.39 (0.90, 2.13)* 1.17 (0.77, 1.77)
AMOXMETTET 1.01 (0.75, 1.38) 0.95 (0.65, 1.41) 1.01 (0.65, 1.59) 1.19 (0.86, 1.65) 1.02 (0.68, 1.53)
AMOXMET 0.89 (0.66, 1.20) 1.17 (0.79, 1.73) 1.14 (0.76, 1.70) 1.27 (0.90, 1.78) 1.09 (0.73, 1.63)
TET 1.05 (0.76, 1.44) 1.01 (0.63, 1.62) 0.97 (0.66, 1.43) 1.02 (0.71, 1.46) 0.95 (0.62, 1.45)
SURGAMOXMETTET 0.94 (0.70, 1.25) 0.94 (0.67, 1.31) 1.01 (0.71, 1.44) 1.25 (0.86, 1.81) 0.98 (0.68, 1.41)
There were no significant reductions in orange complex counts that were observed in all treatment groups compared to SRP.
$Incidence rate ratioexp (b).
%SURG was performed 3 months after the baseline visit. Results shown at the 3-month study period were for SRP.
*Significant results at a0.05.
**Significant results at a0.01.
SURGsurgery; AMOXamoxicillin; METmetronidazole; TETtetracycline; IRRincidence rate ratios.
Fig. 1. Box-plot showing the median distribution of Actinomyces counts by treatment group at baseline. Treatments 18 are
SRP, surgery (SURG)AMOXMET, SURGTET, SURG, AMOXMETTET, AMOXMET, TET, and SURG
AMOXMETTET, respectively. Minimal variations in the median distributions of the counts can be seen. The circles in
the plot indicate outliers.
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Fig. 3. Box-plot showing the median distribution of the red complex counts by treatment at baseline. Treatments 18 are SRP,
surgery (SURG)AMOXMET, SURGTET, SURG, AMOXMETTET, AMOXMET, TET, and SURGAMOX
METTET, respectively. Lesser counts of the red complex were observed at baseline in the SURGTET and SURG
AMOXMETTET-treated groups. The circles in the plot indicate outliers.
Fig. 2. Changes in natural log counts of Actinomyces at each study time point from baseline. Study time points 16 correspond
to baseline, 3, 6, 12, 18, and 24 months, respectively. Lower counts in all treatment groups can be seen at 3 months compared to
baseline counts. Compared to the reference group SRP, subjects in the AMOXMETTET and TET groups had lesser counts
between baseline and 3 months.
Effects of periodontal treatment on bacterial counts
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There were minimal variations in the median distribu-
tions of the purple complex counts at baseline as shown
in the box-plots of Fig. S2A. As shown in Fig. S2,
decreases in counts of the purple complex were observed
between baseline and 3 months in all treatments except
in the SURG-treated group. However, there were no
significant changes in counts of the purple complex
that were observed in all treatment groups as shown in
Table S2. Similar to the box-plots of Fig. S2A, minimal
variations in the median distributions of the green com-
plex counts were also observed as shown in Fig. S3A.
Figure S3 shows that compared to SRP, much lesser
Fig. 5. Box-plot showing the median distribution of orange complex counts by treatment at baseline. The treatments 18 are
SRP, surgery (SURG)AMOXMET, SURGTET, SURG, AMOXMETTET, AMOXMET, TET, and SURG
AMOXMETTET, respectively. Again, minimal variations in the median distributions of the counts can be seen.
Fig. 4. Changes in natural log counts of the red complex at each study time point from baseline. Study time points 16
correspond to baseline, 3, 6, 12, 18, and 24 months, respectively. Much lesser counts of the red complex were observed between
baseline and 3 months in subjects who were treated with AMOXMETTET.
Ibrahimu Mdala et al.
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counts of the green complex were observed at 3 months in
the TET and AMOXMETTET-treated groups. As
demonstrated in Table S3, we observed a 42% and 50%
decrease in counts of the green complex after 6 and 12
months, respectively, in subjects treated with SURG.
Actually, all treatments with SURG reduced green counts
at 12 months as shown in Table S3.
Other predictors
We also tested the effects of gender, smoking habits,
nationality, age, PD, accumulation of plaque, BOP,
gingival redness, and CAL as predictors of counts of
the complexes over time.
We did not observe significant differences in counts
of the complexes and Actinomyces between males and
females in sites that had an initial PD of at least 5 mm and
then treated, as shown in Table S4. Red and orange
complexes’ counts significantly increased in smokers by
18% and 8%, respectively. However, smoking significantly
reduced counts of Actinomyces by 10%. Count levels
of the orange and green complexes were significantly lower
in Swedish subjects while Actinomyces counts were sig-
nificantly higher compared to American subjects. Further
increase in PD significantly elevated counts of the red and
orange complexes by 6% and 3% respectively. Counts of
the red complex were also higher in sites that were
bleeding, lost more attachment, and had gingival redness.
Fractional responses
As with count models, we tested the joint significance of
treatment and time (and the interaction) to see the extent
in which the treatments influenced the composition of the
bacteria. Although the overall tests were not significant,
we observed findings that were comparatively similar to
the count responses. For example, in Table S5 (baseline
covariates not presented), we observed a short-term
benefit of using AMOXMETTET. However, just
like the analysis of the count data, there were no
significant benefits that were observed with the other
treatments. The analysis of proportions also showed that
smoking increased the odds of the red complex by 22%,
deeper pockets increased the odds of the red complex
by 7%, the odds of the red complex was 4% higher in
subjects who had experienced further losses in clinical
attachment, and gingival redness and BOP increased the
odds of the red complex by 10% and 8%, respectively.
In the analysis of red counts (Table 3), smoking, deeper
pockets, further losses in attachment, gingival redness,
and BOP elevated the red counts by 18%, 6%, 3%, 12%,
and 10%, respectively.
Discussion
Knowledge suggesting that periodontal pathogens oper-
ate in complexes rather than as single pathogens has led
to changes in treatment approaches to be considered.
Fig. 6. Changes in natural log counts of the orange complex at each study time point from baseline. Study time points 16
correspond to baseline, 3, 6, 12, 18, and 24 months, respectively. Subjects treated with surgery (SURG)TET had lesser counts
at 3 months.
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This study examined over 2 years the effect of different
periodontal therapies, including combinations of thera-
pies on different bacterial species of the subgingival
microbiota present in five different complexes (2) with
the aim of selecting the most beneficial periodontal
therapy. We specifically looked at changes that occur in
severely affected mesiobuccal sites (PD]5 mm). Taking
samples from all sites might have given a better view of
the total cultivable microbiota. However, we know from
previous work that the red and orange complexes are the
ones most related to clinical disease, particularly in terms
of PD. Therefore, we felt that selecting mesiobuccal sites
would give a good overall insight into what happened
with the agents most related to periodontitis as a result of
local/systemic antibiotic treatment. Treatment effects on
single species of the red complex were also examined.
Although short-term improvements in the counts of the
red complex were observed in sites that were treated with
AMOXMETTET, long-term significant effects were
not observed with any of the eight study treatments. We
also examined the effect of BOP, accumulation of plaque,
deeper pockets, and smoking on counts of the complexes.
We believe that these four factors were most important for
diminishing the effects of the study treatments. For
example, about 41% of our study subjects were current
smokers and our study revealed that colonization of sites
by periodontal pathogens was more extensive in smokers
than in non-smokers. This may explain why smokers
are less responsive to periodontal therapies than non-
smokers. In a study by Bagaitkar et al. (32) on tobacco-
induced alterations to P. gingivalishost interactions, the
authors concluded that P. gingivalis adapts and changes
its DNA and membrane proteins in response to cigarette
smoke. This might be one reason why smokers are more
likely to be resistant to periodontal treatment and are
more susceptible to oral disease caused by infection with
P. gingivalis. Secondly, there was evidence of poor oral
hygiene persisting among our study subjects. For example,
SRP was performed in all study subjects at baseline and
yet after only 3 months, 20% of the sites had already
accumulated dental plaque and 21% of the sites bled
on probing. Similar problems were also observed at other
study time points implying that the use of either single
therapy such as TET or combinational therapies such
as AMOXMET had little impact on the counts.
Locally delivered TET has the added advantage of being
site-specific. As noted by Pavia et al. (33), local delivery
systems are capable of producing high local concentration
of agents with very low systemic spillover. However,
the study revealed that the use of TET in severely affected
sites of subjects who also showed evidence of poor oral
hygiene gave no significant improvements in the counts of
either the red or the orange complex.
In chronic periodontitis, we desire treatments that
elevate Actinomyces counts because maintaining a bacter-
ial flora associated with health after treatment is crucial
for the prognosis. However, we did not find evidence that
the periodontal treatments promoted growth of Actino-
myces in severely affected sites. Although SURG has long
been suspected of initiating loss of CAL through a
detrimental effect on osteoblasts, it remains a useful
procedure for effective removal of plaque and elimination
of periodontal pockets. However, the problems that were
observed and discussed above could have also played a
major role in diminishing the effectiveness of SURG.
Normally, the Poisson distribution is recommended for
analyzing count data. However, due to extra variability in
our bacterial data, a suitable model for overcoming the
problem of over-dispersion and correlated observations
was the negative binomial generalized estimating equa-
tion (NB GEE) model. The advantage of the GEE
approach is that it gives consistent parameter estimates
for correctly specified mean structure even if the working
correlation matrix has been misspecified and consistent
standard errors can be obtained by using a robust
sandwich estimator. A major limitation of our analysis
using the GEE approach is that it is generally restricted
to one level of correlation. Whereas mixed models can fit
multiple levels of correlations, for example teeth nested
in subjects, with the GEE approach our analysis was
restricted to ‘within subject’ dependencies only. Alter-
native approaches include using random effects negative
binomial (RENB) and/or the zero-inflated models with
robust standard errors.
An attempt was also made in this study to analyze
proportions of counts and compare these findings to the
results from the analyses of counts. By using proportions,
information about absolute changes in the levels of the
species being investigated is usually lost. The analysis of
proportions in this study aimed at investigating the effect
of the interventions compared to SRP on changes in
the composition of the complexes. However, the findings
were comparatively similar and we did not find any
noteworthy long-term treatment effect.
Whereas in our previous study (1) SURGAMOX
METTET gave the best maintenance of clinical results
over a 2-year period, long-term significant microbiologi-
cal effects were not obtained with any of the treatments,
although sites treated with AMOXMETTET showed
clear reductions in the counts of the red complex after
3 months. The reason for this is not clear. Possibly,
unfavorable post-treatment ecological changes require
some time to develop before re-infection is established.
This supports the notion that we have no concept of the
length of time that separates changes in the subgingival
microbiota and periodontal tissue destruction (34). Also,
initiation of disease does not necessarily coincide with the
detection of disease since there may be a latent period
between them (35).
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In conclusion, short-term reduction in counts of the red
complex in deeper sites were observed with AMOX
METTET. However, the treatments did not produce
significant beneficial changes in counts of the orange
complex and Actinomyces in these sites. After treatment
red and orange complex counts significantly increased in
smokers, and smoking significantly reduced counts of
Actinomyces. Count levels of the orange and green com-
plexes were significantly lower in Swedish subjects, while
Actinomyces counts were significantly higher compared to
American subjects. Further increase in PD significantly
elevated counts of the red and orange complexes. Counts
of the red complex were also higher in sites that were
bleeding, lost more attachment, and had gingival redness.
We found that BOP, accumulation of plaque, deeper
pockets, and smoking had detrimental effects on the
counts of the complexes and believe that these four
factors were mainly responsible for diminishing the
effects of the study treatments. Our study clearly showed
that antibiotic-treated patients tend to suffer relapse of
the microbiota associated with periodontitis unless dental
plaque is prevented from re-accumulating either by self-
inflicted personal oral hygiene or professional mainte-
nance therapy. The importance of monitoring risk
predictors during maintenance therapy such as smoking
and probing depth was also indicated.
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